Penumbra, Inc. (NYSE:PEN) Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lessened its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 25.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,025 shares of the company's stock after selling 2,768 shares during the period. Illinois Municipal Retirement Fund's holdings in Penumbra were worth $2,146,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of PEN. Hurley Capital LLC acquired a new position in shares of Penumbra during the 4th quarter valued at about $56,000. Huntington National Bank raised its stake in Penumbra by 138.7% during the fourth quarter. Huntington National Bank now owns 265 shares of the company's stock worth $63,000 after purchasing an additional 154 shares during the period. Versant Capital Management Inc raised its stake in Penumbra by 893.5% during the first quarter. Versant Capital Management Inc now owns 308 shares of the company's stock worth $82,000 after purchasing an additional 277 shares during the period. Jones Financial Companies Lllp boosted its holdings in Penumbra by 25.0% in the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company's stock valued at $89,000 after purchasing an additional 75 shares during the last quarter. Finally, UMB Bank n.a. grew its stake in shares of Penumbra by 110.4% in the 1st quarter. UMB Bank n.a. now owns 404 shares of the company's stock valued at $108,000 after buying an additional 212 shares during the period. 88.88% of the stock is owned by hedge funds and other institutional investors.

Penumbra Stock Up 0.3%

Shares of PEN stock traded up $0.80 during trading on Thursday, reaching $250.54. The company's stock had a trading volume of 233,847 shares, compared to its average volume of 502,409. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.30 and a quick ratio of 3.68. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $310.00. The company has a market capitalization of $9.70 billion, a price-to-earnings ratio of 236.36, a P/E/G ratio of 2.23 and a beta of 0.47. The stock's 50-day moving average price is $271.10 and its 200 day moving average price is $268.01.

Penumbra (NYSE:PEN - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The business had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. Penumbra had a return on equity of 11.14% and a net margin of 3.41%. The company's revenue was up 16.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.41 earnings per share. On average, research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Stifel Nicolaus set a $318.00 price target on shares of Penumbra and gave the company a "buy" rating in a research report on Thursday, April 24th. UBS Group reissued a "buy" rating and set a $330.00 target price (up previously from $320.00) on shares of Penumbra in a research note on Thursday, April 24th. Bank of America started coverage on Penumbra in a research note on Friday, March 14th. They issued a "buy" rating and a $320.00 price target on the stock. Royal Bank Of Canada increased their price target on Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Finally, Truist Financial boosted their price objective on shares of Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.

Insider Transactions at Penumbra

In other Penumbra news, Director Bridget O'rourke sold 100 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $286.15, for a total transaction of $28,615.00. Following the completion of the transaction, the director owned 5,423 shares in the company, valued at $1,551,791.45. The trade was a 1.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Maggie Yuen sold 2,000 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $299.01, for a total transaction of $598,020.00. Following the completion of the sale, the chief financial officer owned 13,957 shares in the company, valued at $4,173,282.57. The trade was a 12.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 114,210 shares of company stock valued at $31,582,595 over the last quarter. Insiders own 4.20% of the company's stock.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.